{"title":"Serotype and genotype shift detection over two consecutive periods of dengue virus infection in a tertiary care hospital","authors":"Sandhya Bhat K , Mailan Natarajan , Natarajan Vasanthi , Sudhagar Mookkappan , Bhavadharani Pandian , Shashikala Nair , Reba Kanungo","doi":"10.1016/j.ijmmb.2025.100807","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Dengue virus infection in humans can also lead to severe complications like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The World Health Organization (WHO) estimates around 50 to 100 million dengue infections annually, with approximately 500,000 cases of DHF and 22,000 deaths, predominantly among children. The present study aimed at identifying circulating serotypes of dengue virus in patients by molecular techniques. Serotypes detected were correlated with the clinical profiles, complications, and outcomes in these patients.</div></div><div><h3>Methods</h3><div>This study was conducted between October 2019 to September 2022. Institute Ethics Committee approval was obtained (Reference no. IEC: RC/18/59). Serum from patients who tested positive for dengue NS1 antigen (NS1Ag) or anti-dengue immunoglobulin M (IgM) were serotyped by dengue reverse transcriptase polymerase chain reaction (RT-PCR). Clinical data was documented in case report forms and transferred to an Excel spreadsheet, and subsequently analyzed to correlate the dengue virus (DENV) serotype with clinical profile and outcome.</div></div><div><h3>Results</h3><div>The study population included 416 patients, confirmed by Dengue NS1Ag and or anti-Dengue IgM ELISA. Young adults (18–29 yrs) constituted the majority (56 %) of patients. About 85 % of all patients presented with fever, 10.6 % with hemorrhagic fever, and 4.4 % with shock syndrome. Thrombocytopenia with multiple bleeding manifestations was observed in 6.5 % of the patients. The predominant dengue serotype identified was serotype 3 from October 2019 to March 2021, and serotype 2 from April 2021 to September 2022, showing a shift in the serotypes affecting the patients.</div></div><div><h3>Conclusion</h3><div>Continuous sero- and molecular surveillance plays a crucial role in predicting dengue outbreaks and identifying shifts in circulating serotypes during the early phase of the dengue season. It may also play a role in vaccine preparedness for the control of dengue.</div></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"54 ","pages":"Article 100807"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085725000209","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
Dengue virus infection in humans can also lead to severe complications like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The World Health Organization (WHO) estimates around 50 to 100 million dengue infections annually, with approximately 500,000 cases of DHF and 22,000 deaths, predominantly among children. The present study aimed at identifying circulating serotypes of dengue virus in patients by molecular techniques. Serotypes detected were correlated with the clinical profiles, complications, and outcomes in these patients.
Methods
This study was conducted between October 2019 to September 2022. Institute Ethics Committee approval was obtained (Reference no. IEC: RC/18/59). Serum from patients who tested positive for dengue NS1 antigen (NS1Ag) or anti-dengue immunoglobulin M (IgM) were serotyped by dengue reverse transcriptase polymerase chain reaction (RT-PCR). Clinical data was documented in case report forms and transferred to an Excel spreadsheet, and subsequently analyzed to correlate the dengue virus (DENV) serotype with clinical profile and outcome.
Results
The study population included 416 patients, confirmed by Dengue NS1Ag and or anti-Dengue IgM ELISA. Young adults (18–29 yrs) constituted the majority (56 %) of patients. About 85 % of all patients presented with fever, 10.6 % with hemorrhagic fever, and 4.4 % with shock syndrome. Thrombocytopenia with multiple bleeding manifestations was observed in 6.5 % of the patients. The predominant dengue serotype identified was serotype 3 from October 2019 to March 2021, and serotype 2 from April 2021 to September 2022, showing a shift in the serotypes affecting the patients.
Conclusion
Continuous sero- and molecular surveillance plays a crucial role in predicting dengue outbreaks and identifying shifts in circulating serotypes during the early phase of the dengue season. It may also play a role in vaccine preparedness for the control of dengue.
期刊介绍：
Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study.
Review articles, Special Articles or Guest Editorials are accepted on invitation.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
